| 14th week of 2012 patent applcation highlights part 39 |
| Patent application number | Title | Published |
|---|
| 20120083443 | Control of ATP Release by Red Blood Cells and Therapeutic Applications Thereof - The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCS treated with insulin accumulate significantly less cAMP and release significantly less ATP than normal RBCS. Likewise, RBCS of patients suffering from type 2 diabetes (hyperinsulinemia) accumulate significantly less cAMP and release significantly less ATP than normal RBCS. It was further discovered that prostaglandin analogues synergistically work with phosphodiesterase 3B inhibitors to improve or increase cAMP accumulation and ATP release RBCS. Thus the invention is directed to compositions and methods for improving ATP release by RBCS, via administering PDE3B inhibitor or a combination of PDE3B inhibitor and prostaglandin analogue. | 2012-04-05 |
| 20120083444 | Emulsion Method For Preparing Low Residual Solvent Microparticles - The method disclosed herein comprises using a non-polar alkane in the continuous phase of an emulsion process to aid in the removal of dispersed phase solvent from the microparticles. The microparticles can further be subjected to a post-production treatment process, involving a non-polar alkane suspension and a rinse, to further reduce residual dispersed phase solvent levels. | 2012-04-05 |
| 20120083445 | Compositions Containing HC-HA Complex and Methods of Use Thereof - Disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by TSG-6. Further disclosed herein, in certain embodiments, is an HC•HA complex comprising hyaluronan and a heavy chain of IαI, wherein the transfer of the heavy chain of IαI is catalyzed by the TSG-6 like protein. Additionally, disclosed herein are methods of manufacturing said complex and methods of use thereof | 2012-04-05 |
| 20120083446 | NOVEL ALBUMIN-FREE FACTOR VIII FORMULATIONS - An albumin-free Factor VIII formulation comprising, 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; 100 mM to 300 mM NaCl; and a buffering agent. In a further embodiment, the formulation can comprise: 300 mM to 500 mM NaCl; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mM to 5 mM calcium salt; and a buffering agent. | 2012-04-05 |
| 20120083447 | Novel Therapeutic Treatments Using Centhaquin - Methods of treating hypertension, pain, and resuscitative hemorrhagic shock using an adrenergic agent, like centhaquin, are disclosed. The methods treat mammals, including humans. | 2012-04-05 |
| 20120083448 | Parathyroid Hormone Peptides And Parathyroid Hormone-Related Protein Peptides And Methods Of Use - Provided herein are Parathyroid hormone (PTH) peptides and parathyroid hormone-related protein (PTHrP) peptides (e.g., PTH analogs, PTHrP analogs), and related variants, chemical derivatives, fusion polypeptides, multimeric polypeptides, and peptidomimetics, peptoids, the like. Also provided are their use in methods for activating the PTH receptor in a cell (e.g., an osteoblast), methods of treating a subject with bone loss (e.g., by administration of a PTH peptide or PTHrP peptide (e.g., a PTH analog or PTHrP analog)), methods of ameliorating a symptom associated with osteoporosis in a subject, methods of retarding the progression of osteoporosis in a subject, and methods of regenerating bone in a subject. | 2012-04-05 |
| 20120083449 | TREATMENT FOR ANXIETY - The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient. | 2012-04-05 |
| 20120083450 | CEREBROPROTEIN HYDROLYSATE FOR TREATING BRAIN INJURIES AND NEURODEGENERATIVE CONDITIONS EFFECTING THE BRAIN - Cerebroprotein hydrolysate is administered intravenously and/or orally to help treat a range of brain injuries and neurodegenerative conditions effecting the brain including Traumatic Brain Injury (TBI), concussions, injuries resulting from automobile accidents, sports injuries, falls that impact the head, accidents and acts of violence that impact the head and brain including injuries incurred from combat related activities, Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, and other neurological conditions that adversely effect the function of the brain and central nervous system. The types of brain injuries and neurodegenerative conditions that may be treated with cerebroprotein hydrolysate range from mild to severe. Cerebroprotein hydrolysate treatment effectively assists the brain in rebuilding neurons, synapses, and neurological tissue by infusing the brain with specific proteins, neuropeptides, and amino acids to assist with brain repair. | 2012-04-05 |
| 20120083451 | COMPOSITION FOR IMPROVING BRAIN FUNCTION AND METHOD FOR IMPROVING BRAIN FUNCTION - The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, comprising, as an active ingredient, X-Pro-Pro-Y or a salt thereof, wherein X represent Val, Ile or Asn-Ile and Y represent Phe or Leu. | 2012-04-05 |
| 20120083452 | Topical Anesthetic Uses of Szeto-Schiller Peptides - Topical anesthetic compositions include Szeto-Schiller peptides and a dermatologically acceptable carrier, and optionally a vasoconstrictor and tyrosine. A method of providing local analgesia to the skin involves applying to skin the topical anesthetic compositions. | 2012-04-05 |
| 20120083453 | TREATMENT USING NEUBLASTIN POLYPEPTIDES - The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides. | 2012-04-05 |
| 20120083454 | EPH RECEPTOR EXPRESSION IN TUMOR STEM CELLS - The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass. | 2012-04-05 |
| 20120083455 | HYMAN SERUM ALBUMIN-siRNA NANO-SIZED CARRIER SYSTEM - Disclosed are a human serum albumin-siRNA carrier system having siRNA bound to human serum albumin and a user thereof, and especially, human serum albumin-siRNA carrier system, which has a biodegradable covalent bond between human serum albumin polymer and siRNA and is stable in a living body, and a user thereof. | 2012-04-05 |
| 20120083456 | METHODS OF USING IL-31 TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state. | 2012-04-05 |
| 20120083457 | Bortezomib Formulations - A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture. | 2012-04-05 |
| 20120083458 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING INFLAMMATORY DISEASE - The invention features methods of diagnosing inflammatory disease based on the elevated presence microparticles (MP) expressing certain receptors. The invention also features methods of decreasing fibrosis in the liver by administering MP to subjects with liver fibrosis. | 2012-04-05 |
| 20120083459 | USE OF GANGLIOSIDE TO DECREASE PROPAGATION OF MALIGNANT PROSTATE CELLS - Uses of exogenous ganglioside to inhibit the propagation of prostate cancer cells are provided. Gangliosides regulate many cellular processes including cell death. The present disclosure assesses the role of ganglioside in prostate cell growth. Malignant prostate (PC-3) and control (RWPE-1) cells can be cultured with or without ganglioside treatment. Cells can be assayed for differences in cell growth. Supplementation with ganglioside (GD3) can decrease growth of PC-3 cells by 30% compared to controls (p<0.01). Ganglioside can have therapeutic benefit in prostate cancer as demonstrated by decreased growth of malignant PC-3 cells. | 2012-04-05 |
| 20120083460 | READILY WATER-SOLUBLE ISOQUERCITRIN COMPOSITION - Disclosed is a method for improving the solubility of isoquercitrin in water. Also disclosed is a readily water-soluble isoquercitrin composition which has improved solubility in water due to the method. Specifically disclosed is a method for preparing an isoquercitrin inclusion product, which comprises including isoquercitrin in γ-cyclodextrin in the proportion of 2 to 10 mol of γ-cyclodextrin to 1 mol of isoquercitrin. | 2012-04-05 |
| 20120083461 | AGENT FOR INHIBITING PERITONEAL MEMBRANE THICKENING | 2012-04-05 |
| 20120083462 | Pharmaceutical anti-infective composition for inhalation - An anti-infective composition for inhalation, containing, at least an effective amount of an antimicrobial aminoglycoside compound or a salt thereof; and an effective amount of a biofilm modifier which is a macrolide compound or salt thereof. | 2012-04-05 |
| 20120083463 | Insecticidal and Fungicidal Active Compound Combinations - The present invention relates to active compound combinations consisting, firstly, of a known halogen-substituted derivative (component A) and, secondly, of further known pesticidally active compounds (component B), which active compound combinations are suitable for controlling animal and microbial pests. | 2012-04-05 |
| 20120083464 | NEUROPROTECTIVE PROPERTIES OF 5'-METHYLTHIOADENOSINE - The present invention relates to the use of MTA, its pharmaceutically acceptable salts and/or prodrugs thereof as active ingredient in the manufacture of a medicament for the prevention or treatment of nerve cell death or damage, a neuroprotective medicament, a medicament for the regeneration of nerve cells, and a medicament for the prevention or treatment of a neurological or psychiatric disease. The present invention also relates to a method of prevention or treatment of nerve cell death or damage, a method of neuroprotection, a method of regenerating nerve cells and a method of prevention or treatment of a neurological or psychiatric disease. | 2012-04-05 |
| 20120083465 | METHOD FOR BLOCKING LIGATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS (RAGE) - A method and medicament is provided for treating and inhibiting interaction of the receptor for advanced glycation end-products (RAGE) and its ligands using a natural or synthetic sulfated polysaccharide, preferably a 2-O desulfated heparin. The medicament preferably is administered intravenously, by aerosolization, intra-nasally, intra-articularly, intra-thecally, subcutaneously, topically or orally. The medicament is useful for treating a variety of conditions, including diabetes, inflammation, renal failure, aging, systemic amyloidosis, Alzheimer's disease, inflammatory arthritis, atherosclerosis, and colitis. | 2012-04-05 |
| 20120083466 | LIPID CONJUGATES IN THE TREATMENT OF ALLERGIC RHINITIS - Provided herein are methods of treating, suppressing, inhibiting, or preventing allergic rhinitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. | 2012-04-05 |
| 20120083467 | DEODORANT COMPOSITIONS - A deodorant composition contains β-cyclodextrin, a fixative, a preservative, and a solvent. | 2012-04-05 |
| 20120083468 | METHOD FOR PREPARING A MEDICAL SOLUTION FOR THE MANUFACTURE OF A MEDICAMENT FOR PERITONEAL DIALYSIS - A method of preparing a medical solution includes the steps of a) providing a solution having one or more acetylated or deacetylated amino sugar/sugars in at least one compartment of a container at a pH of from 2.5 to 5.0, and b) terminal sterilization of the compartment and the contents therein. The solution can be used for manufacturing a medicament for peritoneal dialysis. | 2012-04-05 |
| 20120083469 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS - Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: | 2012-04-05 |
| 20120083470 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF - Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided. | 2012-04-05 |
| 20120083471 | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same - The present invention relates to novel pharmaceutical compositions containing the same, and methods of use for a variety of therapeutically valuable uses including, but not limited to, treating obesity by inhibiting the activity of Glycerol 3-phosphate acyltransferase (GPAT). | 2012-04-05 |
| 20120083472 | PHARMACEUTICAL COMPOSITION FOR PROMOTING THE HEALING OF WOUNDS AND CONTAINING LYSOPHOSPHATIDIC ACID AND AN ADENYLYL CYCLASE INHIBITOR AS ACTIVE INGREDIENTS - The present invention relates to a pharmaceutical composition for promoting the healing of wounds, containing lysophosphatidic acid and an adenylyl cyclase inhibitor as active ingredients, and more particularly, to a pharmaceutical composition which contains an adenylyl cyclase inhibitor and which promotes the healing of wounds in senescent cells or aged persons having physiological characteristics different than those of young cells or young persons. In addition, the present invention relates to a method for promoting the healing of wounds involving treating a wounded person with an effective dose of the lysophosphatidic acid and adenylyl cyclase inhibitor. | 2012-04-05 |
| 20120083473 | TREATMENT OF CONDITIONS BY TOLL-LIKE RECEPTOR MODULATORS - Provided herein are methods for treating certain conditions, including fibrosis, inflammatory, and autoimmune conditions, with conjugated compounds having Toll-like receptor modulatory activity. | 2012-04-05 |
| 20120083474 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 - Certain heterocyclic amide compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPA1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease. | 2012-04-05 |
| 20120083475 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. | 2012-04-05 |
| 20120083476 | HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE - Certain heteroaryl-substituted spirocyclic diamine urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). | 2012-04-05 |
| 20120083477 | PROTEASOME INHIBITORS AND USES THEREOF - A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors. | 2012-04-05 |
| 20120083478 | CRYSTALLINE OXALATE SALTS OF A DIAMIDE COMPOUND - The invention relates to crystalline oxalate salts of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]-methyl}phenylcarbamoyl)butyl]methylcarbamoyl}ethyl)piperidin-4-yl ester. This invention also relates to compositions containing such a crystalline oxalate salt; methods of using such a crystalline oxalate salt to, for example, treat a pulmonary disorder; and to processes for preparing such a crystalline oxalate salt. | 2012-04-05 |
| 20120083479 | Compositions Comprising Azelastine and Methods of Use Thereof - The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders. | 2012-04-05 |
| 20120083480 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS - This invention relates to a pernasally administrable preparation for the controlled release of sexual hormones to the systemic circulation, in particular to a formulation which enables its active ingredient to be absorbed in a sustained manner providing a better bioavailability at very low doses and longer duration of action. | 2012-04-05 |
| 20120083481 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5. | 2012-04-05 |
| 20120083482 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING - The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds of general formula (A) | 2012-04-05 |
| 20120083483 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 2012-04-05 |
| 20120083484 | CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF - The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer. | 2012-04-05 |
| 20120083485 | NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION - The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone. | 2012-04-05 |
| 20120083486 | KIT, COMPOSITION, PRODUCT OR MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT - A kit, composition, product or medicament for treating cognitive impairment is provided, which includes a therapeutic agent for neurodegenerative disease and a heterocyclic compound represented by the following General Formula (I): | 2012-04-05 |
| 20120083487 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF PSEUDOBULBAR AFFECT, NEUROLGICAL DISEASES, INTRACTABLE AND CHRONIC PAIN AND BRAIN INJURY - Provided herein are compositions comprising a dextromethorphan analog according to Formula I or Formula II or a pharmaceutically acceptable salt thereof of either of the foregoing, and a co-agent, e.g., an antidepressant such as a serotonin norepinephrine reuptake inhibitor; a serotonin noradrenaline dopamine reuptake inhibitor; a norepinephrine dopamine reuptake inhibitor; a monoamine oxidase inhibitor; a selective serotonin reuptake inhibitor; and a tricyclic antidepressant or a pharmaceutically acceptable salt of any of the foregoing. The compositions are useful in the treatment of pseudobulbar affect, neuropathic pain, neurodegenerative diseases, brain injuries, and the like. | 2012-04-05 |
| 20120083488 | TETRACYCLIC COMPOUND - A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: | 2012-04-05 |
| 20120083489 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS - The invention provides novel bis-pyridylpyridones which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), pharmaceutical compositions containing them, processes for their preparation, and their use in therapy and for the treatment of obesity and diabetes. | 2012-04-05 |
| 20120083490 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF - The present invention features compounds of formula I | 2012-04-05 |
| 20120083491 | Combination of Active Substances with Insecticidal Properties - The invention relates to novel insecticidal active compound combinations comprising, firstly, compounds which act as insecticides on nicotinergic acetylcholine receptors as agonists and antagonists, and at least one active compound from the group of the anthranilamides, which combinations are suitable for protecting plants against attack by pests. | 2012-04-05 |
| 20120083492 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS - There is provided compounds of formula (I), wherein R | 2012-04-05 |
| 20120083493 | SMALL-MOLECULE MODULATORS OF TRP-P8 ACTIVITY - Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression. | 2012-04-05 |
| 20120083494 | NOVEL TRIAZOLE DERIVATIVES WITH IMPROVED RECEPTOR ACTIVITY AND BIOAVAILABILITY PROPERTIES AS GHRELIN ANTAGONISTS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS - The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy). | 2012-04-05 |
| 20120083495 | COMPOUNDS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY AND OTHER USES - Compounds useful for the treatment of spinal muscular atrophy or other uses, as well as methods of using such compounds to increase SMN expression, increase EAAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift. | 2012-04-05 |
| 20120083496 | ISOXAZOLE COMPOUND FOR THE TREATMENT OF CANCER - The use of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide or a tautomer thereof or a pharmaceutically acceptable salt or a hydrate or a solvate for the treatment of cancer of the bladder, the colon, the liver, the lung, the breast, the vagina, the ovaries, the pancreas, the kidney, the stomach, the gastrointestinal tract, the prostate, the head and neck, the peritoneal cavity, the thyroid, the bone, the brain, the central nervous system and/or the blood and/or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, multicentric Castleman disease and/or psioriasis. | 2012-04-05 |
| 20120083497 | Method for Combating Harmful Fungi - The present invention relates to methods, use and compositions for combating harmful fungi and bacteria in plants. More specifically, it relates to methods and compositions for controlling, preventing, or treating plant pathogens using UV filters for combating phytotoxin-producing fungi and/or bacteria, in particular, for combating harmful fungi and/or bacteria producing photodynamically active phytotoxins. | 2012-04-05 |
| 20120083498 | Modulators of Viral Transcription, and Methods and Compositions Therewith - Processes to treat human immunodeficiency virus (HIV) infection are included. | 2012-04-05 |
| 20120083499 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS - The present application relates to calcium channel inhibitors comprising compounds of formula (I), formula (II), formula (III), or formula (IV), | 2012-04-05 |
| 20120083500 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X 2/3 ANTAGONISTS - Compounds of the formula I: | 2012-04-05 |
| 20120083501 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES - The invention provides novel tricyclic compounds of Formula I′ that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases. | 2012-04-05 |
| 20120083502 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2012-04-05 |
| 20120083503 | METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF CHEMOTHERAPY ON NON-SMALL-CELL LUNG CANCER - This invention relates to an antitumor agent comprising carboplatin and a combination drug of tegafur/gimeracil/oteracil potassium to be administered to a cancer patient selected according to an expression level of thymidylate synthase gene. | 2012-04-05 |
| 20120083504 | Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof - The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6. | 2012-04-05 |
| 20120083507 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namelyl, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 2012-04-05 |
| 20120083508 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN - Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed. | 2012-04-05 |
| 20120083509 | Synergistically active mixtures of alpha,omega-amino alcohol enantiomers, preparation thereof and use thereof in insect- and mite-repellent formulations - What are described are insect- and mite-repellent compositions comprising at least 2 enantiomers selected from the group of 1-[(S)-sec-butyloxycarbonyl]-2-(S)-(2-hydroxyethyl)piperidine (referred to hereinafter as S,S), 1-[(R)-sec-butyloxycarbonyl]-2-(R)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as R,R), 1-[(S)-sec-butoxycarbonyl]-2-(R)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as S,R), 1-[(R)-sec-butyloxycarbonyl]-2-(S)-(+)-(2-hydroxyethyl) piperidine (referred to hereinafter as R,S), excluding the racemate mixture thereof, a process for preparation thereof and the use thereof in insect- and mite-repellent formulations. | 2012-04-05 |
| 20120083510 | PERFLUOROCARBONS FOR USE IN TREATING PRURITUS - The subject application provides a method of treating pruritus comprising administering to the skin of a subject afflicted with pruritus an amount of a perfluorocarbon effective to treat the pruritus. The subject application also provides a method of alleviating a symptom of psoriasis comprising administering to the skin of a subject afflicted with psoriasis an amount of a perfluorocarbon effective to alleviate the symptom of psoriasis. The subject application also provides a perfluorocarbon composition for use in treating a subject afflicted with pruritus or psoriasis. The subject application further provides a pharmaceutical composition comprising an amount of a perfluorocarbon for use in treating pruritus or psoriasis. | 2012-04-05 |
| 20120083511 | CRYSTALLINE (R)-(E)-2-(4-(2-(5-(1-(3,5-DICHLOROPYRIDIN-4-YL)ETHOXY)-1H-INDAZOL-3-YL)V- INYL)-1H-PYRAZOL-1-YL)ETHANOL - The present invention provides crystalline (R)-(E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol useful in the treatment of cancer. | 2012-04-05 |
| 20120083512 | PHARMACEUTICAL PRODUCT FOR INJECTION - The claimed subject matter is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container and closure are made of material which essentially does not release zinc ions. | 2012-04-05 |
| 20120083513 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds of the following formula, wherein -A and —B are as defined herein (collectively referred to herein as 38TM compounds): | 2012-04-05 |
| 20120083514 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG - The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R | 2012-04-05 |
| 20120083515 | BIOADHESIVE GEL BASED ON HYDROXYETHYLCELLULOSE - Disclosed are compositions in the form of a bioadhesive gel that adheres to the mucous membranes, in particular the vaginal mucosa, for the application of active ingredients and/or principles, comprising hydroxyethylcellulose as the only gelling agent. | 2012-04-05 |
| 20120083516 | Nasal sinus spray for treatment of sinus headache and method of using same - Disclosed is a nasal spray containing the combination of a vasoconstrictor and a topical local anesthetic. | 2012-04-05 |
| 20120083517 | POLYMORPHS OF SAXAGLIPTIN HYDROCHLORIDE AND PROCESSES FOR PREPARING THEM - The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride. | 2012-04-05 |
| 20120083518 | Cancer Treatment Targeting BRCA1-IRIS - Patients identified as candidates at risk of developing aggressive cancer, including metastatic cancer, are determined based on the expression of BRCA1-IRIS. In one advantageous form, the expression of BRCA1-IRIS is quantified based on BRCA1-IRIS present in tumor cells of patients. The amount of BRCA1-IRIS expression can be quantified in any conventionally known manner, including quantifying the amount of protein present in tumor cells or BRCA1-IRIS mRNA present in tumor cells of patients. | 2012-04-05 |
| 20120083519 | Methods For Diagnosing And Treating A Renal Disease In An Individual - A method for diagnosing a renal disease in an individual, comprising: a) measuring the level of expression of c-mip in a renal sample of the individual; b) comparing the level of expression of c-mip to a predetermined value; and c) determining therefrom whether the individual is afflicted with a renal disease. Furthermore, a method for treating a renal disease, comprising administration of a c-mip inhibitor. | 2012-04-05 |
| 20120083520 | Ghrelin binding nucleic acids - The present invention is related to a nucleic acid antagonist of ghrelin. | 2012-04-05 |
| 20120083521 | Aptamers as agonists - Nucleic acid aptamers are described herein which can transduce a signal into cells by crosslinking a cell surface molecule, thereby inducing of one or more biological activities by the cells; in serving as agonists. | 2012-04-05 |
| 20120083522 | MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI - Disclosed herein are antisense compounds and methods for modulating Factor XI and modulating an inflammatory disease, disorder or condition in an individual in need thereof. Inflammatory diseases in an individual such as arthritis and colitis can be ameliorated or prevented with the administration of antisense compounds targeted to Factor XI. | 2012-04-05 |
| 20120083523 | MEDICAL DEVICES HAVING POLYMERIC REGIONS WITH COPOLYMERS CONTAINING HYDROCARBON AND HETEROATOM-CONTAINING MONOMERIC SPECIES - According to an aspect of the present invention, implantable or insertable medical devices are provided, which contain one or more polymeric regions. These polymeric regions, in turn, contain one or more polymers, at least one of which is a copolymer that includes the following: (a) one or more unsaturated hydrocarbon monomer species and (b) one or more heteroatom-containing monomer species. | 2012-04-05 |
| 20120083524 | Oral Composition Comprising DHA and Genistein for Enhancing Skin Properties - Composition for oral consumption in the form of a substantially 5 homogeneous aqueous emulsion, suspension or dispersion comprising genistein and docosahexaenoic acid (DHA) and less than 1% by weight of soy protein, wherein the weight ratio of genistein to DHA is in the range of from 1:100 to 1:1, the composition comprises genistein in an amount of from 0.0001% to 0.1% by 10 weight and the genistein and DHA exhibit an anti-ageing effect on skin. | 2012-04-05 |
| 20120083525 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASES MEDIATED BY THE ACTIVATION OF AMPK AND INCLUDING 2,5-BIS-ARYL-3,4-DIMETHYLTETRAHYDROFURAN LIGNANS AS ACTIVE INGREDIENTS - The present invention relates to a 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan compound which activates nutmeg-derived AMP-activated protein kinase (AMPK), and to a composition including same as active ingredients for preventing and treating metabolic syndromes such as obesity. More particularly, the present invention relates to an AMPK-activating compound comprising one of the 2,5-bis-aryl-3,4-dimethyltetrahydrofuran lignan-based compounds produced by extracting | 2012-04-05 |
| 20120083526 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON - The present invention relates in general to the field of organic chemistry and in particular to the preparation of 1-(2,3-dihydrobenzofuran-4-yl)ethanone, an intermediate in preparation of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide, i.e. ramelteon. | 2012-04-05 |
| 20120083527 | Anticancer Agents - The present disclosure relates generally to compositions and methods for treating cancer. In some aspects, novel spirohexenolides and methods of using and producing them are described. | 2012-04-05 |
| 20120083528 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF - The present invention provides new tyrphostin derivatives acting as protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, and/or which directly or indirectly affect proteins in the PTK-mediated signal transduction pathway, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer. | 2012-04-05 |
| 20120083529 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS - The present invention relates to methods of treating benign hyperproliferative diseases of the epidermis by administering a composition comprising at least one jasmonate ester derivative, preferably methyl jasmonate. In particular, the present invention provides jasmonate ester derivatives as potent compounds useful for the treatment of disorders such as actinic keratoses with reduced side effects. | 2012-04-05 |
| 20120083530 | Thermally Stable Oil-in-Water Emulsions Containing an Oil That Contains Polyunsaturated Fatty Acids - The present invention relates to thermally stable oil-in-water emulsions comprising an oil comprising a polyunsaturated fatty acid, water, an emulsifier, and a water-soluble stabilizer, and processes for preparing the thermally stable oil-in-water emulsions. The thermally stable oil-in-water emulsions remain flowable at a temperature of −40° C., and are free from a variation in particle size after 9 months in storage at a temperature of −40° C. to −15° C. | 2012-04-05 |
| 20120083531 | CALCIUM CITRATE AND CALCIUM LACTATE FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING - The present invention relates to pharmaceutical compositions suitable for inhalation, comprising as an active ingredient calcium lactate or calcium citrate. The invention also relates to methods of treating, preventing, and reducing the spread of an infection of the respiratory tract, comprising administering a pharmaceutical composition that comprises calcium lactate or calcium citrate as an active ingredient. | 2012-04-05 |
| 20120083532 | NOVEL USES - The present invention relates to the use of a compound represented by the general formula (I), and pharmaceutically acceptable salts thereof, wherein: n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hydroxyl group, an alkoxy group, a thiol group, a thioether group, and an amino group, wherein at least two of R | 2012-04-05 |
| 20120083533 | USE OF AMIDES OF MONO- AND DICARBOXYLIC ACIDS IN THE TREATMENT OF RENAL DISEASES - A therapy for renal diseases, in particular renal diseases which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, the present invention relates to palmitoylethanolamide and diethanolamide of fumaric acid for use in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution. | 2012-04-05 |
| 20120083534 | OPHTHALMIC AND CONTACT LENS SOLUTION - An ophthalmic solution comprising a polyethoxylated glyceride in the range of 0.001 to about 10 percent by weight and a buffer agent. These solutions impart surprising comfort and wearability to contact lenses. At the same time the solutions provide good preservative capacity and do not increase protein deposit. | 2012-04-05 |
| 20120083535 | ADHESIVE MIXTURE FOR TRANSDERMAL DELIVERY OF HIGHLY PLASTICIZING DRUGS - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 2012-04-05 |
| 20120083536 | ANTIMICROBIAL ADHESIVE SYSTEM - An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided. | 2012-04-05 |
| 20120083537 | TCD BASED HYDROPHILIC POLYURETHANE DISPERSIONS - The present invention relates to a polyurethaneurea solution having a polyurethaneurea having a structural unit of the formula (I) | 2012-04-05 |
| 20120083538 | PROCESS FOR GENERATION OF SYNTHETIC FUEL FROM CARBONACEUS SUBSTANCES - A method and apparatus for the generation of synthetic motor fuels and additives to oil fuels, C | 2012-04-05 |
| 20120083539 | Process for Preparing Methanol, Dimethyl Ether, and Low Carbon Olefins from Syngas - The present invention provides a process for preparing methanol, dimethyl ether, and low carbon olefins from syngas, wherein the process comprises the step of contacting syngas with a catalyst under the conditions for converting the syngas into methanol, dimethyl ether, and low carbon olefins, characterized in that, the catalyst contains an amorphous alloy consisting of components M and X wherein the component X represents an element B and/or P, the component M represents two or more elements selected from Group IIIA, IVA, VA, IB, IIB, IVB, VB, VIB, VIIB, VIII and Lanthanide series of the Periodic Table of Elements. According to the present process, the syngas can be converted into methanol, dimethyl ether, and low carbon olefins in a high CO conversion, a high selectivity of the target product, and high carbon availability. | 2012-04-05 |
| 20120083540 | METHOD FOR THE PREPARATION OF A HYDROCARBON SYNTHESIS CATALYST MATERIAL AND THE USE THEREOF IN A HYDROCARBON SYNTHESIS PROCESS - This invention relates to a method for the preparation of a hydrocarbon synthesis catalyst material, in the form of a hydrocarbon synthesis catalyst precursor and/or catalyst, preferably, a Fischer Tropsch synthesis catalyst precursor and/or catalyst. The invention also extends to the use of a catalyst precursor and/or catalyst prepared by the method according to the invention in a hydrocarbon synthesis process, preferably, a Fischer Tropsch synthesis process. According to this invention, a method for the preparation of a hydrocarbon synthesis catalyst material includes the steps of treating Fe(II) carboxylate in solution with an oxidising agent to convert it to Fe(III) carboxylate in solution under conditions which ensure that such oxidation does not take place simultaneously with any dissolution of Fe(0); and hydrolysing the Fe(III) carboxylate solution resulting from step (iii) and precipitating one or more Fe(III) hydrolysis products. | 2012-04-05 |
| 20120083541 | AROMATIC POLYETHER SULFONE BLOCK COPOLYMERS - An aromatic polyether sulfone block copolymer comprises hydrophilic segments which have sulfonic acid groups and hydrophobic segments which have no sulfonic acid groups, wherein the proportion by weight of hydrophilic segments is from 0.02 to 0.35. | 2012-04-05 |
| 20120083542 | METHOD FOR TREATING WASTES - The present invention relates to a process for the treatment of waste in a reactor ( | 2012-04-05 |
| 20120083543 | POROUS MATERIAL HAVING IMPROVED COMPRESSIVE STRENGTH AND METHOD OF MAKING SAME - A method of forming a porous material having improved compressive strength includes forming an aerogel precursor, the aerogel precursor including a matrix material and a liquid dispersion medium for dispersing the matrix material. A freeze/thaw cycle is performed on the aerogel precursor, the freeze/thaw cycle including freezing the aerogel precursor so that the dispersion is solidified and thawing the aerogel precursor to liquefy the frozen dispersion medium. The aerogel precursor is frozen so that the dispersion is solidified, and freeze dried to sublime the dispersion medium and form the porous material. | 2012-04-05 |
| 20120083544 | REINFORCED MICROCELLULAR URETHANE PRODUCTS - A microcellular urethane composition, comprising a polyol component, an isocyanate component having an isocyanate index ratio of from about 65 to about 145; and up to about 50% by weight of a nano-scale filler dispersed throughout the composition. Methods for producing a reinforced microcellular urethane component are also provided. | 2012-04-05 |
